EPA和DHA经调节肌源性IL-6表达改善脂质代谢紊乱的作用及机制研究

近年研究表明，白细胞介素6（IL-6）不只是一种炎性因子，还是骨骼肌分泌的一种重要肌动蛋白，肌源性IL-6因参与脂质代谢调节而备受关注，有望成为改善脂质代谢紊乱的新靶点。本课题组前期研究发现EPA和DHA均能上调小鼠骨骼肌IL-6的表达和分泌，并可能与其对脂质代谢的改善作用相关。本项目拟在前期研究的基础之上，以正常和特异性敲除骨骼肌IL-6基因的C57/BL6J小鼠和C2C12肌管细胞、3T3-L1脂肪细胞系作为实验对象，系统研究EPA和DHA经调节肌源性IL-6表达及分泌对脂质代谢的改善作用，并从TRPV1/PKC/Ca2+和AMPK/STAT3通路阐明其内在机理。其研究结果将为合理摄入EPA和DHA以改善脂质代谢紊乱提供新的理论依据，为相关慢性病的早期防治提供新的思路和途径，有重要理论价值和现实意义。

Recent studies have shown that interleukin 6 (IL-6) is not only an inflammatory factor, but also an important myokine secreted by skeletal muscle. Muscle-derived IL-6, an expected target for lipid metabolism disorders therapies, has received much attention because of its regulation of lipid metabolism. Our previous research found that both EPA and DHA up-regulated the expression and secretion of muscle-derived IL-6 in mice, which may be involved in the regulation of lipid metabolism. Based on that, the present study aims to systematically investigate the effect of EPA and DHA on muscle-derived IL-6 expression and secretion to improve lipid metabolism disorders, and elucidate the possible underlying mechanism mediated via TRPV1/PKC/Ca2+ and AMPK/STAT3 pathway using wild type C57/BL6J mice, muscle-derived IL-6 knockout mice C2C12 myotubes and 3T3-L1 adipocytes. Results of the present study will provide a new scientific evidence for reasonable intakes of EPA and DHA to improve lipid metabolism disorders, a new perspective and approach for the early prevention and treatment of lipid metabolism disorders and its related non-communicable chronic diseases.